What is CNS Pharmaceuticals's earnings per share (EPS)?

CNS Pharmaceuticals (CNSP) reported diluted earnings per share of $-35.75 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CNS Pharmaceuticals Financials

CNSP

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows CNS Pharmaceuticals (CNSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, CNS Pharmaceuticals generates $0.87 in operating cash flow (-$13.8M OCF vs -$15.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1049.7x

CNS Pharmaceuticals earns $-1049.7 in operating income for every $1 of interest expense (-$16.0M vs $15K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$16.0M

YoY-7.3%

CNS Pharmaceuticals's EBITDA was -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.3% from the prior year.

Net Income

-$15.9M

YoY-6.7%

CNS Pharmaceuticals reported -$15.9M in net income in fiscal year 2025. This represents a decrease of 6.7% from the prior year.

EPS (Diluted)

$-35.75

CNS Pharmaceuticals earned $-35.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 8.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$13.8M

YoY+19.2%

CNS Pharmaceuticals generated -$13.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 19.2% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

811,449

CNS Pharmaceuticals had 811,449 shares outstanding in fiscal year 2025. This represents an increase of 588.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$9.8M

YoY+5.2%

5Y CAGR+14.1%

CNS Pharmaceuticals invested $9.8M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$18K

YoY+334.0%

5Y CAGR+0.3%

CNS Pharmaceuticals invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 334.0% from the prior year.

CNSP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.8M+5.2%	$9.3M-34.1%	$14.1M+51.6%	$9.3M-5.2%	$9.8M+93.7%	$5.1M
SG&A Expenses	$6.2M+10.7%	$5.6M+17.7%	$4.8M-20.1%	$6.0M+27.5%	$4.7M+6.6%	$4.4M
Operating Income	-$16.0M-7.3%	-$14.9M+21.0%	-$18.9M-23.6%	-$15.3M-5.4%	-$14.5M-53.2%	-$9.5M
Interest Expense	$15K-5.5%	$16K+16.8%	$14K+96.5%	$7K-24.3%	$9K+184.5%	$3K
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$15.9M-6.7%	-$14.9M+21.2%	-$18.9M-23.4%	-$15.3M-5.4%	-$14.5M-53.3%	-$9.5M
EPS (Diluted)	$-35.75	$-38.87	$-12509.11	$-11.22+32.0%	$-16.50	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.2M+88.2%	$1.2M-64.0%	$3.2M	N/A	$4.2M+280.2%	$1.1M-54.1%	$2.4M	N/A
SG&A Expenses	$1.1M-15.0%	$1.2M+13.5%	$1.1M	N/A	$1.4M-2.0%	$1.4M+26.7%	$1.1M	N/A
Operating Income	-$3.3M-35.0%	-$2.4M+44.5%	-$4.3M	N/A	-$5.6M-122.7%	-$2.5M+28.7%	-$3.5M	N/A
Interest Expense	$2K-49.4%	$4K-32.6%	$6K	N/A	$2K-49.4%	$4K-32.6%	$7K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.2M-35.5%	-$2.4M+44.8%	-$4.3M	N/A	-$5.6M-121.5%	-$2.5M+28.6%	-$3.5M	N/A
EPS (Diluted)	$-5.76+10.3%	$-6.42	$-1.58	N/A	$-153.20+96.2%	$-4049.20	$-1020.48	N/A

CNSP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$8.7M+411.6%	$1.7M-87.0%	$13.1M+49.1%	$8.8M-44.8%	$15.9M
Current Assets	N/A	$8.7M+444.2%	$1.6M-87.3%	$12.6M+68.0%	$7.5M-51.7%	$15.5M
Cash & Equivalents	N/A	$6.5M+1077.5%	$549K-94.5%	$10.1M+100.9%	$5.0M-64.4%	$14.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$2.5M-58.8%	$6.1M+24.6%	$4.9M+89.7%	$2.6M+36.1%	$1.9M
Current Liabilities	N/A	$2.5M-58.8%	$6.1M+24.6%	$4.9M+89.7%	$2.6M+36.1%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$6.2M+239.4%	-$4.4M-154.5%	$8.1M+32.0%	$6.2M-55.8%	$13.9M
Retained Earnings	N/A	-$84.4M-21.4%	-$69.6M-37.2%	-$50.7M-43.1%	-$35.4M-69.2%	-$20.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$11.9M-18.2%	$14.5M+5.5%	$13.7M+58.0%	$8.7M+17.4%	$7.4M+200.1%	$2.5M+48.7%	$1.7M-2.4%	$1.7M
Current Assets	$11.4M-19.4%	$14.1M+3.0%	$13.7M+58.5%	$8.7M+17.2%	$7.4M+244.4%	$2.1M+34.0%	$1.6M+0.6%	$1.6M
Cash & Equivalents	$9.9M-18.7%	$12.1M-7.0%	$13.0M+101.9%	$6.5M-7.3%	$7.0M+367.5%	$1.5M+83.0%	$815K+48.6%	$549K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.0M+41.7%	$1.4M-50.2%	$2.8M+10.1%	$2.5M-37.8%	$4.1M-40.0%	$6.8M+11.0%	$6.1M-0.7%	$6.1M
Current Liabilities	$2.0M+41.7%	$1.4M-50.2%	$2.8M+10.1%	$2.5M-37.8%	$4.1M-40.0%	$6.8M+11.0%	$6.1M-0.7%	$6.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.9M-24.5%	$13.1M+19.6%	$11.0M+77.6%	$6.2M+84.2%	$3.4M+178.1%	-$4.3M+3.1%	-$4.4M0.0%	-$4.4M
Retained Earnings	-$94.3M-3.5%	-$91.1M-2.7%	-$88.7M-5.1%	-$84.4M-3.9%	-$81.2M-7.4%	-$75.6M-3.5%	-$73.1M-5.1%	-$69.6M

CNSP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13.8M+19.3%	-$17.1M-21.0%	-$14.1M-33.9%	-$10.6M+22.0%	-$13.5M-85.0%	-$7.3M
Capital Expenditures	$18K+334.0%	$4K+7.4%	$4K-11.8%	$4K-23.1%	$6K-68.0%	$18K
Free Cash Flow	-$13.8M+19.2%	-$17.1M-21.0%	-$14.1M-33.9%	-$10.6M+22.0%	-$13.5M-84.6%	-$7.3M
Investing Cash Flow	-$18K-334.0%	-$4K-7.4%	-$4K+11.8%	-$4K+23.1%	-$6K+68.0%	-$18K
Financing Cash Flow	$14.6M-36.7%	$23.0M+396.6%	$4.6M-70.3%	$15.6M+246.3%	$4.5M-68.1%	$14.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.2M+59.3%	-$5.3M-64.8%	-$3.2M+40.7%	-$5.5M+19.5%	-$6.8M-312.0%	-$1.7M+48.3%	-$3.2M-25.9%	-$2.5M
Capital Expenditures	N/A	N/A	N/A	$4K	N/A	N/A	N/A	$2K
Free Cash Flow	N/A	N/A	N/A	-$5.5M	N/A	N/A	N/A	-$2.5M
Investing Cash Flow	N/A	N/A	N/A	-$4K	N/A	N/A	N/A	-$2K
Financing Cash Flow	-$92K-102.1%	$4.4M-55.0%	$9.8M+98.0%	$5.0M-59.6%	$12.3M+427.8%	$2.3M-32.7%	$3.5M+58.8%	$2.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNSP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-240.6%	N/A	-187.8%+47.4pp	-235.2%-167.4pp	-67.8%
Return on Assets	N/A	-170.8%+937.6pp	-1108.3%-991.3pp	-117.0%+48.5pp	-165.5%-105.9pp	-59.7%
Current Ratio	N/A	3.43+3.2	0.26-2.3	2.55-0.3	2.88-5.3	8.13
Debt-to-Equity	N/A	0.41+1.8	-1.38-2.0	0.60+0.2	0.42+0.3	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-32.5%-14.4pp	-18.1%+21.1pp	-39.2%	N/A	-167.2%	N/A	N/A	N/A
Return on Assets	-27.1%-10.7pp	-16.4%+14.9pp	-31.3%	N/A	-75.7%+26.8pp	-102.5%+110.9pp	-213.4%	N/A
Current Ratio	5.81-4.4	10.22+5.3	4.94+1.5	3.43+1.6	1.82+1.5	0.32+0.1	0.260.0	0.26
Debt-to-Equity	0.20+0.1	0.11-0.1	0.25-0.2	0.41-0.8	1.21+2.8	-1.58-0.2	-1.370.0	-1.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Quoin Pharmaceuticals Ltd QNRX

$10.8M

Oragenics OGEN

$2.6M

Jaguar Health Inc JAGX

$5.0M

THERIVA BIOLOGICS INC TOVX

$13.6M

Xenetic Biosciences Inc XBIO

$7.0M

Frequently Asked Questions

Is CNS Pharmaceuticals profitable?

No, CNS Pharmaceuticals (CNSP) reported a net income of -$15.9M in fiscal year 2025.

What is CNS Pharmaceuticals's EBITDA?

CNS Pharmaceuticals (CNSP) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is CNS Pharmaceuticals's free cash flow?

CNS Pharmaceuticals (CNSP) generated -$13.8M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CNS Pharmaceuticals's operating cash flow?

CNS Pharmaceuticals (CNSP) generated -$13.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CNS Pharmaceuticals's capital expenditures?

CNS Pharmaceuticals (CNSP) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does CNS Pharmaceuticals spend on research and development?

CNS Pharmaceuticals (CNSP) invested $9.8M in research and development during fiscal year 2025.

How many shares does CNS Pharmaceuticals have outstanding?

CNS Pharmaceuticals (CNSP) had 811,449 shares outstanding as of fiscal year 2025.

Are CNS Pharmaceuticals's earnings high quality?

CNS Pharmaceuticals (CNSP) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CNS Pharmaceuticals cover its interest payments?

CNS Pharmaceuticals (CNSP) has an interest coverage ratio of -1049.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.